arrow
J

Jonathan M. E. Hughes

Merck and Co. Inc.
H指数:16
被引数:1,125

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Biocatalytic Oxidative Desymmetrization of the Substituted Pyrrolidine Intermediate of MK-7845: An Investigational Antiviral Therapy for COVID-19

MK-7845的取代吡咯烷中间体的生物催化氧化不对称反应:一种用于COVID-19的探索性抗病毒疗法

2026-03-110
PRE
Asymmetric Synthesis of KRAS G12C Inhibitor MK-1084 via a Crystallization-Induced Diastereomer Transformation (CIDT)

通过结晶诱导的非对映体转化 (CIDT) 不对称合成KRAS G12C抑制剂MK-1084

2026-01-010
PRE
Asymmetric Synthesis of MK-7845, an Investigational Treatment for COVID-19

MK-7845的不对称合成,新型冠状病毒肺炎的研究性治疗

2025-10-010
PRE
Cerastecin Inhibition of the Lipooligosaccharide Transporter MsbA to Combat Acinetobacter baumannii: From Screening Impurity to In Vivo Efficacy
2024-08-220
PRE
Rapid End-Game Process Development and First GMP Production of MK-7845: An Experimental Antiviral Treatment for COVID-19
2024-06-062
PRE
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer
2021-03-2320
PRE